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Several papers in the present symposium emphasize the 
importance and interplay of carbohydrate and fat metabo- 
lism during exercise of varying intensities and duration. In 
constrast, amino acid metabolism is deemed to make only a 
minimal contribution to the provision of energy for the 
working muscle and is, with few exceptions, ignored. 
Equally, the mechanisms of what is termed ‘central 
fatigue’, i.e. fatigue associated with alterations in the 
functioning of the brain or central nervous system (CNS), 
are largely unexplored. However, several papers over the 
past few years have promoted an attractive role for certain 
amino acids as substrates for intermediary metabolism and 
precursors of brain neurotransmitters. The focus of the 
present paper is the potential interplay between peripheral 
substrate utilization, amino acid metabolism, brain neuro- 
transmitter function and fatigue. For the purpose of the 
present symposium only experimental data obtained from 
human subjects will be considered. 
Fatigue during exercise is commonly defined as the 
inability to maintain the required force or power output. In 
the present discussion, fatigue, or the perception of fatigue, 
is considered to be related to the loss of power output, or 
the perceived inability to maintain power output, during 
prolonged submaximal dynamic exercise. Fatigue during 
this type of exercise can be conveniently partitioned into 
‘central’ and ‘peripheral’ components (Fig. 1). 
Much is now known of the role of substrate depletion in 
the aetiology of fatigue (see relevant papers in the present 
symposium) but subjects performing prolonged exercise 
perceive an increase in fatigue well in advance of the point 
where substrate depletion (or other components of 
peripheral fatigue) forces the subject either to stop or to 
reduce the required intensity of exercise. This perception of 
fatigue must reside within the brain and CNS, is thought to 
be related to a change in brain neurotransmitters such as 
serotonin (5-hydroxytryptamine), noradrenaline and dopa- 
mine, and is generally known as the ‘central fatigue 
hypothesis’. In essence, the central fatigue hypothesis 
suggests that an increase in brain serotoninergic function in 
response to an increase in the blood-borne delivery of its 
amino acid precursor, tryptophan, can impair certain 
aspects of CNS function (possibly by reducing dopaminer- 
gic activity) in order to induce an early onset of fatigue 









Fig. 1. Central and peripheral components of fatigue and the putative links in 
communication between them. CNS, central nervous system. 
Abbreviations: BCAA, branched-chain amino acids; CNS, central nervous system; K,(,pp,TRp, apparent K, for tryptophan; LNAA, large neutral amino 
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acids; Vozm,, maximum 0 2  uptake. 
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The concept of a central fatigue hypothesis probably 
originated from nutritional studies by Fernstrom & Wurt- 
man (1971, 1972) and much of the interest in the 
relationship between nutrition, brain neurochemistry and 
sports performance in human subjects can be traced back to 
this work. In a series of papers these authors described the 
effect of manipulating, by dietary means, the plasma 
concentration of amino acids on amino acid entry into 
brain. Amino acids do not readily enter across the blood- 
brain barrier and have to be transported by means of a 
carrier or transporter. The large neutral amino acid 
(LNAA)-transporter is a saturable carrier that shares its 
transporter function between six amino acids: tyrosine, 
tryptophan, phenylalanine, and the branched-chain amino 
acids (BCAA) leucine, isoleucine and valine. The apparent 
affinity of the LNAA transporter, and hence the relative 
rate of transport into brain of the individual amino acid, 
depends on the concentration of each amino acid relative to 
its competitors. Of interest in the present discussion is the 
manipulation of the relative rate of entry of the amino 
acid precursors of brain monoamines, i.e. tyrosine, as a 
precursor for the catecholamines, and tryptophan as a 
precursor for serotonin (Fernstrom, 1990). Of the six 
competing amino acids for the LNAA transporter, trypto- 
phan has the lowest concentration in plasma (50 p~), with 
approximately 90 % of the tryptophan associated with 
plasma albumin and approximately 10 % i.e. 5 pM in the 
free form. The plasma concentration of the competing five 
LNAA is approximately 10-fold higher (i.e. 500 p~), which 
equates to a value for free tryptophan : LNAA of 1 : 100 and 
an apparent K, for tryptophan (K,(,,,,TRP) of l a  (van 
Hall et al. 1995). Studies in rats had shown that 
manipulation of the plasma amino acid composition to 
change the free typtophan : LNAA value was known to alter 
the rate of entry of tryptophan into brain and to increase the 
synthesis and subsequent metabolism of serotonin in brain 
(Chauloff, 1989). In the knowledge that tryptophan 
concentration in dietary protein is lower than that of the 
other amino acids competing for the LNAA transporter, 
Fernstrom (1983) was able to demonstrate that the intake of 
a protein-rich meal effectively increased KmfappTRP and 
thereby brain tryptophan concentrations remained largely 
unchanged, whereas feeding a high-carbohydrate diet 
provoked an insulin-induced clearance of several of the 
competing amino acids, decreased the Km(app,TRp and 
promoted an influx of tryptophan into the brain. The 
putative behavioural effects of an increased synthesis of 
brain serotonin, as a result of the increase in brain 
typtophan, i.e. lethargy, sleep and fatigue (Young, 1986), 
made this an attractive proposition for those investigating 
the link between exercise-induced changes in peripheral 
amino acid metabolism, brain neurotransmitter function 
and fatigue, i.e. the ‘central fatigue hypothesis’ as proposed 
by Newsholme et al. (1987). 
According to these arguments it is possible to analyse the 
experimental data published to date and to test the validity of 
the ‘central fatigue hypothesis’. For clarity the experimental 
data are considered in three sections: 
1. manipulation of the BCAA and/or tryptophan concen- 
trations in the circulation (peripheral effect); 
2. pharmacological manipulation of brain monoaminergic 
3. cross-sectional and longitudinal training studies (geno- 
function (central effect); 
typical and phenotypical response). 
Manipulation of plasma BCAA andor tryptophan 
concentrations 
Several studies have attempted to manipulate the influx of 
tryptophan into brain and hence, according to the central 
fatigue hypothesis, endurance performance by nutritional 
intervention. The first, and most applied, study was that of 
Blomstrand et al. (1991) who investigated the effect of 
feeding 16g of a mixture of BCAA on the performance 
of marathon runners. The BCAA cocktail was composed of 
valine, leucine and isoleucine in the proportions 50 : 35 : 15 
in a solution containing 50 g carbohydratek Oral ingestion 
of the BCAA drink elevated plasma BCAA levels by 140 % 
and decreased the plasma free tryptophan:BCAA by 
180 %, but had no overall effect on marathon performance 
in the faster runners, i.e. those completing the marathon in 
less than 3 h  5min, but was associated with a small 
improvement in performance (approximately 3 %) in the 
slower runners. In a similar study by the same group 
(Newsholme et al. 1991), no significant change in exercise 
performance resulted from feeding the same BCAA 
cocktail to athletes competing in a 24km event. There are 
obvious limitations to field-based studies, and later 
controlled studies in the laboratory were undertaken to 
verify these early results. Varnier et al. (1994) infused 
approximately 20 g BCAA or saline (9 g NaClA) over the 
70min period before exercise and found no difference in 
performance in a graded exercise test to fatigue. The 
conclusion from this study was to cast doubt on the validity 
of the central fatigue hypothesis, although it could equally 
be argued that the short-term incremental test used in this 
study was not an appropriate exercise challenge to test the 
central fatigue hypothesis as originally stated. Of the 
controlled laboratory studies in this area the paper by van 
Hall et al. (1995) is by far the most comprehensive. In this 
study, endurance-trained cyclists were fed on either a low 
(2 g/l) or high (6 gA) concentration of BCAA in a solution 
containing 60 g sucrosefl, which increased the plasma 
BCAA concentration at exhaustion by approximately 2- 
and 5-fold for the low- and high-BCAA drinks respectively. 
Compared with a placebo, neither the low- nor high-BCAA 
condition had any influence on cycle performance times to 
exhaustion at 70% maximum 0 2  uptake (VO2&. Again 
these findings would not appear to support the central 
fatigue hypothesis. However, the lack of any significant 
change in exercise performance following BCAA feeding 
is fully justified from a consideration of the underlying 
biochemistry relating to the process of transport of 
tryptophan and other competing amino acids into brain. 
From the experimental data it was possible to determine the 
effect that the change in circulating BCAA levels had on 
K m f a p p ~ R P  for the amino acid transporter and thereby, from 
Michaelis-Menten kinetics, the change in unidirectional 
flux of free tryptophan into the brain (Table 1). As 
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mentioned previously, resting concentrations of competing 
LNAA ( K ~ ( ~ ~ ~ T ~  approximately 1 M) effectively act to 
restrict the entry of free tryptophan into the brain 
(calculated unidirectional influx of 2-6 nmoVmin per mg). 
In the control or placebo condition, prolonged exercise acts 
to decrease circulating BCAA levels and increase circulat- 
ing free tryptophan levels, resulting in a decrease in the 
Km(app;RP and an approximate 3-fold increase in the influx 
of tryptophan into brain. When similar calculations are 
made from the experimental data obtained from the 
subjects following feeding of either the low- or high- 
BCAA drinks, the resultant changes in tryptophan influx 
into the brain, compared with the placebo condition, are 
minimal (Table 1). Considering the relatively small overall 
effect that any change in circulating concentrations of 
amino acid precursors of monoamine synthesis may have 
on brain monoamine function, it is totally reasonable that 
such small decreases in the rate of influx of free tryptophan 
brought about by BCAA feeding were found to have no 
effect on endurance performance. Furthermore, any nutri- 
tional strategy that delivers high concentrations of BCAA 
to muscle must take account of the increase in the 
production of metabolites of amino acid oxidation by 
muscle, i.e. glutamine and NH3. Buffering of the NH3 load 
in muscle leads to the efflux of high concentrations of 
glutamine, a process which can drain the muscle of 
intermediates of the tricarboxylic acid cycle and conceiv- 
ably impair the muscle’s capacity for oxidative metabolism 
(Wagenmakers et al. 1991), and thereby contribute to a 
peripheral cause of fatigue. Equally, efflux of N H 3  from 
muscle results in elevated plasma and brain NH3 concen- 
trations, which can lead to an impairment of motor function 
and/or produce symptoms of fatigue independent of any 
change in brain monoamine function (Banister & Cameron, 
1990). 
An alternative nutritional intervention that can be applied 
to investigate the role of amino acid precursors of brain 
monoamine synthesis in the aetiology of the fatigue process 
is to manipulate tryptophan availability directly. Feeding 
tryptophan elevates total tryptophan levels in the circula- 
tion, saturating the binding capacity of plasma albumin, and 
thereby significantly elevating the level of free tryptophan 
available for transport across the blood-brain barrier. The 
assumption in this strategy is that by increasing plasma 
tryptophan, and thereby tryptophan availability to the brain, 
the resultant increase in serotoninergic action would reduce 
exercise performance time. Early attempts to test this 
hypothesis were flawed in their experimental design by the 
lack of any measurement of changes in the independent 
variable, i.e. plasma tryptophan, and in the choice of the 
exercise challenge, i.e. high-intensity exercise lasting less 
than lOmin in duration. Paradoxically, it was found that 
pre-ingestion of a total of 1.2g tryptophan (four doses of 
300mg each) produced an increase in treadmill perfor- 
mance time at 80% of Vo,,, (Segura & Ventura, 1988) 
but had no effect on treadmill performance at 100% of 
Vo,m, (Stensrud et al. 1992); the analgesic action of 
tryptophan was cited as the reason for the increase in 
performance in the former study. Later studies using an 
endurance-based exercise challenge (bicycle exercise at 
70 % VoZmax) in which the plasma tryptophan concentration 
was elevated %fold (by ingestion of a total of 3.9g 
tryptophan) before exercise showed no effect on exercise 
performance when compared with a placebo (van Hall et al. 
1995). The absence of effect on exercise performance 
occurred in the presence of an estimated 20-fold increase in 
free tryptophan influx into brain (Table I), which seriously 
questions the validity of the central fatigue hypothesis to 
attenuate exercise performance by a mechanism which 
alters tryptophan availability to brain. 
The opposing action, i.e. to decrease tryptophan avail- 
ability and thereby reduce the influence of plasma 
tryptophan on the fatigue process, can be attained either 
by maintaining the majority of tryptophan in association 
with plasma albumin, therefore rendering tryptophan 
unavailable for transport across the blood-brain barrier, or 
to reduce the influence of tryptophan by removal of 
tryptophan from the circulation. Carbohydrate feeding has a 
well-known suppressive effect on the mobilization of fatty 
acids that compete with tryptophan for binding sites on 
plasma albumin and such a nutritional intervention should 
reduce, or negate, the increase in plasma free tryptophan 
Table 1. Calculated changes in apparent K,, of tryptophan ( K m ( e p p F )  and unidirectional influx ( v )  of free tryptophan following experimental 
manipulation of the plasma concentration of branched-chain amino acids (BCAA) and tryptophan (Adapted from van Hall et a/. 1995) 
(Mean values and standard deviations) 
Control Tryptophan BCAAI.3, BCAAhigh 
Mean SD Mean SD Mean SD Mean SD 
Tryptophan (pmol/l) Pre 44 7 47 6 44 5 45 10 
exh 43 7 304 61 40 6 38 7 
BCAA (pmol/l) Pre 443 92 47 1 35 521 160 450 54 
exh 380 42 372 22 947 186 2397 483 
v free tryptophan Pre 2.6 













pre, pre-exercise; exh, at exhaustion; BCAA,,,, 2 g BCANI; BCAAhigh, 6 g BCANI  
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levels during prolonged exercise. Davis et al. (1 992) tested 
the hypothesis that carbohydrate feeding would minimize 
the central component of the fatigue process and thereby 
prolong endurance, by feeding subjects 5 mVkg per h of a 
carbohydrate-electrolyte solution. This strategy suppressed 
the normal rise (5-7-fold) in plasma free tryptophan levels 
during prolonged exercise at 70% V+,,a, and increased 
overall performance time by approximately 1 h. Although it 
was not possible to partition the beneficial effects of 
carbohydrate feeding on central v. peripheral mechanisms 
of fatigue, the substantial increase in endurance perfor- 
mance could not be explained by changes in physiological 
indices of peripheral muscle fatigue, and provided a 
measure of support to the central fatigue hypothesis. Other 
nutritional strategies designed to achieve the same effect 
include previous feeding of an amino acid mix deplete of 
tryptophan designed to significantly reduce (>80 %) 
plasma tryptophan availability (Young et al. 1985), but 
exercise trials using this experimental paradigm have not 
yet been completed successfully (E Venning and PM 
Jakeman, unpublished results). 
Pharmacological manipulation of brain monoaminergic 
function 
Many authors would argue that the evidence presented in 
the previous section does not consistently support the 
central fatigue hypothesis, and indeed the balance of the 
experimental data from studies using nutritional strategies 
would side against the existence of any influence of altered 
serotoninergic action in response to changes in the delivery 
of blood-borne tryptophan to the brain. Few, however, 
would argue against the influence that pharmacologically- 
induced alterations in serotoninergic function have on 
endurance performance in the rat (for example, see Bailey 
et al. 1993). But what evidence is there that similar effects 
are seen in human studies? 
Recent advances in the pharmacology of drugs used to 
probe specific neurotransmitter action in human subjects 
have provided the exercise scientist with an alternative 
approach to investigate the role of the brain monoaminergic 
function in the aetiology of fatigue. However, several 
difficulties are encountered when performing these studies. 
These include: 
non-selectivity of drug action; 
differential actions of drugs when used as an acute, 
single-dose mode compared with the action of the drug 
when given repeatedly or after a short course of treat- 
ment; 
inter-individual sensitivity of subject response to a fixed 
amount of drug; 
the inability to measure, and therefore control for, the 
degree of agonist or antagonist action, i.e. poor control 
of the independent variable. 
Recognizing these limitations, pharmacological agonists 
and antagonists of brain serotoninergic function have been 
used in human studies of exercise performance and to 
investigate the adaptation of brain serotoninergic function 
to exercise training (Table 2). In general, the actions of 
these drugs have been shown to be specific to central 
(brain) neurotransmitter function with no change in 
peripheral neurotransmitter action, as indicated by normal 
cardio-respiratory and metabolic responses to exercise in 
the drug trial. Wilson & Maughan (1992) were the first to 
study the effects of a single oral dose of a serotoninergic 
agonist (20 mg Paroxetine) on bicycle exercise time to 
exhaustion at 70% Vozmax in well-trained subjects. The 
medm exercise time to exhaustion following a single dose 
of paroxetine was found to be 19 % less ( P  = 0.036) than 
with a placebo, which the authors conclude is evidence of a 
component to fatigue mediated by an increase in the 
activity of serotoninergic neurones in brain. It must be 
recognized, however, that although the drug is known to 
increase serotoninergic action in the raphe nuclei of the 
brain, projection areas from the raphe nuclei tend to exhibit 
reduced serotoninergic activity following acute application 
of this type of drug. The complexity of these drug 
interactions may explain, in part, why later studies have 
not been able to fully corroborate these early findings. 
Using the same exercise protocol and a generically-similar 
drug (70mg Fluoxetine), Davis et al. (1993) reported a 
slight (9 %), but not statistically different, decrease in cycle 
performance time, whilst Jakeman et al. (1994~) reported 
no change in treadmill endurance time at 60% in 
response to a generically-different serotoninergic agonist, 
D-Fenfluramine (30 mg, oral). Using the opposite approach 
to antagonize brain serotoninergic action, Pannier et al. 
(1995) studied the effects of a single dose of the anti- 
migrane agent Pizotifen, a known serotoninergic antago- 
nist, on treadmill endurance performance at 70% VoZmax. 
Table 2. Studies of the effect of pharmacological manipulation of brain serotoninergic function on human endurance exercise performance 
(Mean values and standard deviations) 
Endurance time (min) 
Reference Regimen 
Placebo Drug Statistical significance 
of difference 
Mean SD Mean SD between groups: P 
Wilson & Maughan (1992) 20mg Paroxetine, cycle at 70%Vo2, 116 (86-133)* 94 (84-127)* 0,036 
Davis et a/. (1 993) 70 mg Fluoxetine, cycle at 70 % VO, 126 8.1 115 9.0 < 0.05 
Hawthorne & Jakernan (1 995) 30 mg Fenfluramine, treadmill at 60 % VO2,, 134 41 135 31 0.89 
Pannier eta/. (1995) 1 mg Pizotifen, treadmill at 70% Vo2, 119.8 12.5 109.4 6.7 > 0.05 
~ 
VO~,,,,, maximum O2 uptake. 
'Mean values and ranges shown in parentheses. 
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Compared with a placebo, endurance time in the anti- 
serotoninergic trial decreased ( P  > 0.05) in seven of the 
eight subjects in this study. The data on human subjects, 
therefore, are inconclusive, although, since the use of 
pharmacological agents as ‘probes’ of brain neurotransmit- 
ter function and in the investigation of the ‘central’ 
component has yet to be fully established, there are 
exciting prospects for their future use. 
Cross-sectional and longitudinal training studies 
It is intriguing to know whether the lower perception of 
effort reported by endurance-trained athletes when com- 
pared with non-trained subjects exercising at the same 
absolute and/or relative exercise intensity could be 
accounted for by changes in peripheral amino acid 
metabolism, brain monoamine function and the central 
fatigue hypothesis as outlined in the previous two sections. 
In relation to the peripheral metabolism and the availability 
of amino acid precursors of brain monoamines, it is 
somewhat of a paradox that the increase in fat oxidation in 
the endurance-trained athletes occurs with an overall 
reduction in plasma non-esterified fatty acids (Hurley et 
al. 1989). This would suggest that the amount of tryptophan 
dissociated from plasma albumin (i.e. free tryptophan) 
would be less in the trained athlete than in non-trained 
subjects. Equally, endurance training leads to an elevated 
total muscle glycogen concentration and a sparing of 
muscle glycogen during submaximal exercise. This would 
indicate a lower requirement for amino acid oxidation by 
the exercising muscle to maintain tricarboxylic acid cycle 
intermediates, lower extraction of plasma BCAA and a 
higher circulating BCAA level (see pp. 36-38) in the 
trained athlete. Overall, therefore, it is to be expected that 
the ratio of competing amino acids for the L-amino acid 
transporter in brain would be weighted against tryptophan 
entry into brain; a factor that may account for the lower 
perception of effort in endurance-trained athletes. In a 
previous study it was possible to analyse the difference 
between highly-endurance-trained athletes and non-active 
controls in response to prolonged submaximal treadmill 
exercise to exhaustion. The data (Table 3) showed that, 
despite a lower concentration of circulating non-esterified 
fatty acids, the free tryptophan was slightly higher in the 
endurance-trained athletes and combined with the predicted 
increase in circulating BCAA levels, that the overall free 
tryptophan : BCAA value was not significantly different in 
endurance-trained subjects during prolonged submaximal 
exercise to exhaustion. 
In the absence of any significant effect of endurance 
training on the plasma free tryptophan : BCAA ratio during 
prolonged exercise it could be hypothesized that the 
training effect leading to a lower perception of effort in 
the trained subjects is mediated by changes in the 
sensitivity of brain serotoninergic function. Using a 
pharmacological ‘probe’ of brain serotoninergic function 
(Buspirone) and an indirect neuro-endocrine marker of 
serotoninergic activity (prolactin) Jakeman et al. (19946) 
were able to demonstrate a down-regulation of serotoni- 
nergic activity in response to a serotoninergic agonist in 
endurance-trained athletes compared with healthy, non- 
trained controls. The magnitude of the decrease in response 
in this cross-sectional comparison suggested a modification 
of central (brain) serotoninergic function, but could not 
distinguish whether the response was inherent to the 
subjects, or occurred as a result of an adaptation to 
prolonged endurance training. In a recent study, the same 
Table 3. Comparison of plasma metabolite responses to prolonged treadmill exercise to exhaustion at 60% maximum oxygen uptake in 
endurance-trained and non-trained subjects (Adapted from Jakeman et a/. 1994a) 
(Mean values and standard deviations) 
Trained Untrained Statistical significance 
of difference between 
Mean SD Mean SD groups: P 
Glucose (mmoVI) Pre 5.2 0.2 5.1 0.1 0.897 
exh 3.8 0.4 4.6 0.2 
NEFA (pmol/l) 173 17 201 26 
exh 1007 138 1205 180 
Free tryptophan (pmol/l) Pre 4-0 0.3 3.6 0.2 
exh 7-8 0.7 6.3 0.5 
LNAA (pmolll) Pre 508 28 473 20 
exh 51 0 16 449 22 




Prolactin (mU/I) Pre 277 52 406 78 






pre, pre-exercise; exh, at exhaustion; NEFA, non-esterified fatly acids; LNAA, large neutral amino acids. 
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research group have performed a similar longitudinal study 
of the effect of 16 weeks of endurance training on 
previously non-trained subjects. Preliminary data indicate 
a mean decrease, approximating to 30%, in response to a 
serotoninergic agonist following 16 weeks of endurance 
training (Jakeman et al. 1997). These preliminary findings 
would support the view that central monoaminergic 
function is implicated in the fatigue process and can be 
modified by endurance training. 
Summary and conclusions 
Although fatigue during prolonged exercise has tradition- 
ally been associated with peripheral factors relating to 
muscle metabolism, such as the depletion of muscle 
glycogen, more recent research has generated a renewed 
interest in amino acid metabolism per se and in the role of 
amino acids as precursors of brain neurotransmitter 
function. The concept of a ‘central fatigue hypothesis’ 
has done much to stimulate scientists to explore the 
functional role of the brain and CNS in the aetiology of the 
fatigue process. The concept has also generated a number 
of testable hypotheses by which it is possible to examine 
how the ‘central’ component of fatigue may act. The 
present review has attempted to bring together the current 
research in this area. 
There is good reason to believe that nutritional 
intervention may play an important role in relation to 
fatigue residing within the brain and CNS. Although an 
exciting possibility exists that nutritional manipulation may 
affect brain neurochemistry and ultimately sports perfor- 
mance, the experimental evidence to support this claim is, 
as yet, equivocal. A greater understanding of amino acid 
metabolism and, in particular, amino acid transport, will 
greatly improve future experimental designs used to test 
the efficacy of nutritional manipulation of amino acids 
and their effect on the central component of the fatigue 
process. 
References 
Bailey SP, Davis JM & Ahlbom EN (1993) Neuroendocrine and 
substrate responses to altered brain 5-HT activity during 
prolonged exercise to fatigue. Journal of Applied Physiology 
74, 3006-3012. 
Banister WW & Cameron BJC (1990) Exercise-induced hyper- 
ammonemia: Peripheral and central effects. International 
Journal of Sports Medicine 11, S129-S142. 
Blomstrand E, Hassmen P, Ekblom B & Newsholme EA (1991) 
Administration of branched-chain amino acids during sustained 
exercise - effects on performance and on plasma concentration 
of some amino acids. European Journal of Applied Physiology 
and Occupational Physiology 63, 83-88. 
Chauloff F (1989) Physical exercise and brain monoamines: a 
review. Acta Physiologica Scandinavica 137, 1-13. 
Davis JM, Bailey SP, Jackson DA, Strasner AB & Morehouse SL 
(1993) Effects of a serotonin (5-HT) agonist during prolonged 
exercise to fatigue in humans. Medicine and Science in Sport 
and Exercise 78, Suppl., 438. 
Davis JM, Bailey SP, Woods JA, Galiano FJ & Hamilton M 
(1992) Effect of carbohydrate feedings on plasma free- 
tryptophan and branched-chain amino acids during prolonged 
cycling. European Journal of Applied Physiology 65,513-519. 
Fernstrom JD (1983) Role of precursor availability in the control 
of monoamine biosynthesis in brain. Physiological Reviews 63, 
484-546. 
Femstrom JD (1990) Aromatic amino acids and monoamine 
synthesis in the central nervous system: influence of the diet. 
Journal of Nutritional Biochemistry 1, 508-5 17. 
Fernstrom JD & Wurtman RJ (1971) Brain serotonin content: 
physiological dependence on plasma tryptophan levels. Science 
Fernstrom JD & Wurtman RJ (1972) Brain serotonin content: 
physiological regulation by plasma neutral amino acids. Science 
178,414-416. 
Hawthorne JE & Jakeman PM (1995) Exercise-induced changes 
in serum prolactin as an index of serotoninergic activity in 
endurance trained and non-endurance trained subjects. Journal 
of Sports Sciences 13, 32-33. 
Hurley BF, Nemeth PM, Martin WH 111, Hagberg JM, Dalsky GP 
& Holloszy JO (1986) Muscle triglyceride utilization during 
exercise: effect of training. Journal of Applied Physiology 60, 
Jakeman PM, Greenhow S, Maxwell SRJ, Kendall MJ & Jones 
DA (1997) Endurance training of previously non-trained 
subjects modifies the neuroendocrine response to a serotoni- 
nergic agonist. Experimental Physiology (In the Press). 
Jakeman PM, Hawthorne JE, Maxwell SRJ & Kendall MJ (1994a) 
Changes in circulating amino acid precursors of brain 
monoamine synthesis and of prolactin during prolonged 
exhaustive exercise in endurance-trained and non-endurance 
trained subjects. Clinical Science 87, 52-53. 
Jakeman PM, Hawthorne JE, Maxwell SRJ, Kendall MJ & Holder 
G (19946) Evidence of downregulation of hypothalamic 5-  
hydroxytryptamine receptor function in endurance-trained 
athletes. Experimental Physiology 79, 461-464. 
Newsholme EA, Acworth IN & Blomstrand E (1987) Amino 
acids, brain neurotransmitters and a functional link between 
muscle and brain that is important in sustained exercise. In 
Advances in Myochemistry, pp. 127-138 [G Benzi, editor]. 
London: John Libbey Eurotext. 
Newsholme EA, Blomstrand E, Hassmen P & Ekblom P 
(1991) Physical and mental fatigue: do changes in plasma 
amino acids play a role? Biochemical Society Transactions 19, 
Pannier JL, Bouckaert JJ & Lefebvre RA (1995) The antiserotonin 
agent pizotifen does not increase endurance performance in 
humans. European Journal of Applied Physiology 72, 175- 
178. 
Segura R & Ventura JL (1988) Effect of L-tryptophan supple- 
mentation on exercise performance. International Journal of 
Sports Medicine 9, 301-305. 
Stensrud T, Ingjer F, Holm H & Stromme SB (1992) L- 
Tryptophan supplementation does not improve running 
performance. International Journal of Sports Medicine 13, 
481-485. 
van Hall G, Raaymakers JSH, Saris WHM & Wagenmakers AJM 
(1995) Ingestion of branched-chain amino acids and tryptophan 
during sustained exercise in man: faiiure to affect performance. 
Journal of Physiology 486, 789-794. 
Varnier M, Sarto P, Martines D, Lora L, Carmignoto F, Leese G & 
Naccarato R (1994) Effect of infusing branched-chain amino 
acid during incremental exercise with reduced muscle glyco- 





Nutritional aspects of exercise 41 
Wagenmakers AJM, Bechers EJ, Brouns F, Kuipers H, Soeters 
PB, van der Vusse GJ & Saris WHM (1991) Carbohydrate 
supplementation, glycogen depletion, and amino acid metabo- 
lism during exercise. American Journal of Physiology 260, 
Wilson WM & Maughan RJ (1992) Evidence for a possible role of 
5-hydroxytryptamine in the genesis of fatigue in man: 
administration of paroxetine, a 5-HT re-uptake inhibitor, 
E883-E890. 
reduces the capacity to perform prolonged exercise. Experi- 
mental Physiology 77, 921-924. 
Young SN (1986) The clinical pharmacology of tryptophan. In 
Nutrition and the Brain, vol. 7 ,  pp. 49-88 [RJ Wurtman and JJ 
Wurtman, editors]. New York: Raven. 
Young SN, Smith SE, Pihl RO & Ervin FR (1985) Tryptophan 
depletion causes a rapid lowering of mood in normal males. 
Psychopha~acology 87, 173-1 77. 
0 Nutrition Society 1998 
